Rocilinostat (ACY-1215): HDAC6 Inhibition in Cancer Research

Executive Summary: Rocilinostat (ACY-1215) is a potent and selective small-molecule inhibitor of histone deacetylase 6 (HDAC6) with an IC50 of 5 nM, exhibiting over 1,000-fold selectivity over other HDAC isoforms, according to the APExBIO product documentation. This compound increases acetylation of α-tubulin, disrupts cancer cell viability, and augments apoptosis in multiple myeloma models, particularly when used with proteasome inhibitors. In vivo, Rocilinostat delays tumor progression and prolongs survival in xenograft mice without notable toxicity. The compound's selectivity profile and robust solubility in DMSO make it suitable for advanced oncology and translational neurobiology research. Recent studies also suggest an intersection between HDAC6 inhibition and neural development, broadening its utility in disease modeling (see related article).

Biological Rationale

HDAC6 is a cytoplasmic deacetylase that modulates non-histone substrates, including α-tubulin and HSP90. Its overexpression is strongly associated with tumorigenesis, promoting cancer cell survival, proliferation, and metastatic dissemination (see benchmark article). HDAC6 is also implicated in the regulation of protein homeostasis via the aggresome pathway, relevant for both oncogenesis and neurodegeneration. Inhibiting HDAC6 disrupts essential processes in malignant cells, notably affecting microtubule dynamics and the cellular response to misfolded proteins (Product Info).

Importantly, recent neurobiological studies highlight a parallel between epigenetic mechanisms in cancer and those governing neural development and primary cilia function (Rocilinostat & Neural Development). This article expands upon such findings, contrasting them with previous studies that focused solely on cancer cell pathways.

Mechanism of Action of Rocilinostat (ACY-1215)

Rocilinostat (ACY-1215) specifically targets the deacetylase activity of HDAC6, resulting in hyperacetylation of α-tubulin and disruption of microtubule function. The compound exhibits an IC50 of 5 nM for HDAC6, with minimal activity on HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, sirtuins 1/2, and only slight inhibition of HDAC8. This selectivity minimizes off-target effects and cytotoxicity (APExBIO).

The inhibition of HDAC6 leads to impaired trafficking and removal of misfolded proteins, increased apoptosis, and reduced metastatic potential in cancer cells. In multiple myeloma, HDAC6 inhibition sensitizes tumor cells to proteasome inhibitors, enhancing anti-myeloma efficacy even in drug-resistant models (see recent review).

Evidence & Benchmarks

• Rocilinostat (ACY-1215) demonstrates an HDAC6 inhibition IC50 of 5 nM in biochemical assays (APExBIO).
• Selective inhibition is confirmed by negligible activity against other Class II HDACs and sirtuins 1/2; slight activity is observed only for HDAC8 (product data).
• In vitro, Rocilinostat increases acetylated α-tubulin levels and reduces viability in multiple myeloma cells, especially in combination with bortezomib or carfilzomib (review).
• In vivo oral dosing in xenograft mouse models delays tumor growth and prolongs survival, with no significant toxicity reported at effective dosages (APExBIO).
• Rocilinostat is soluble in DMSO at concentrations ≥21.675 mg/mL but insoluble in water or ethanol, supporting its use in cell-based assays (specification).

Applications, Limits & Misconceptions

Rocilinostat (ACY-1215) is a preferred tool for dissecting HDAC6-dependent pathways in oncology and neurobiology. Its use in multiple myeloma cell viability assays has provided insight into synergistic anti-myeloma effects with bortezomib, including in drug-resistant cells (recent review). Moreover, selective HDAC6 inhibition offers a more targeted approach than pan-HDAC inhibitors, reducing risk of broad cytotoxicity.

Emerging evidence suggests a cross-domain relevance between cancer epigenetics and neural development, as HDAC6 is also involved in primary cilia biology—a theme explored in recent studies of SMPD4-driven sphingolipid metabolism (see SMPD4 review). This article clarifies the mechanistic overlap and updates previous cancer-centric focus to include neurodevelopmental implications.

Common Pitfalls or Misconceptions

• Rocilinostat is not effective against HDAC4, HDAC5, HDAC7, HDAC9, or HDAC11; its selectivity must be considered in experimental design (product data).
• It is intended for research use only and is not approved for clinical or diagnostic applications.
• Stock solutions in DMSO should not be stored long-term; prompt use is recommended to avoid compound degradation (storage guidelines).
• Rocilinostat is insoluble in water and ethanol, limiting its use in certain in vivo or aqueous formulations.
• Not all tumor types are sensitive to HDAC6 inhibition; efficacy should be validated per model system.

Workflow Integration & Parameters

• Stock Solution Preparation: Dissolve Rocilinostat in DMSO to a final concentration ≥21.675 mg/mL for cell-based assays; do not use water or ethanol as solvents.
• Storage: Store powder at -20°C. Use DMSO solutions immediately; avoid long-term storage to prevent loss of activity.
• Cell Viability Assay: For multiple myeloma research, treat cells with 0.1–5 μM Rocilinostat for 24–72 hours, with or without proteasome inhibitors (bortezomib or carfilzomib), per established protocols (protocol review).
• Animal Model Dosing: For in vivo studies, administer Rocilinostat orally at 50–100 mg/kg/day in xenograft mouse models; monitor for signs of toxicity and tumor progression.
• Shipping: Product is shipped cold (blue ice) and should be processed promptly upon arrival (shipping info).

Conclusion & Outlook

Rocilinostat (ACY-1215) from APExBIO is a validated, selective HDAC6 inhibitor, providing high-precision tools for cancer and neurodevelopmental research. Its robust selectivity profile and efficacy in multiple myeloma models are now complemented by emerging evidence of relevance in neural development and primary cilia biology (see neural implications). Future work may further elucidate the cross-domain applications of HDAC6 inhibition, building on current preclinical findings and leveraging the compound's unique properties. Investigators are encouraged to consult the A4083 product page for the latest validated protocols and handling recommendations.